CA2102120A1 - Utilisation d'un derive 1,3-oxathlolane pour le traitement de l'hepatite b - Google Patents

Utilisation d'un derive 1,3-oxathlolane pour le traitement de l'hepatite b

Info

Publication number
CA2102120A1
CA2102120A1 CA002102120A CA2102120A CA2102120A1 CA 2102120 A1 CA2102120 A1 CA 2102120A1 CA 002102120 A CA002102120 A CA 002102120A CA 2102120 A CA2102120 A CA 2102120A CA 2102120 A1 CA2102120 A1 CA 2102120A1
Authority
CA
Canada
Prior art keywords
compound
formula
hepatitis
treatment
oxathiolan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002102120A
Other languages
English (en)
Inventor
Phillip Allen Furman Jr.
George Robert Painter Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2102120A1 publication Critical patent/CA2102120A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002102120A 1991-05-02 1992-05-01 Utilisation d'un derive 1,3-oxathlolane pour le traitement de l'hepatite b Abandoned CA2102120A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919109506A GB9109506D0 (en) 1991-05-02 1991-05-02 Therapeutic nucleosides
GB9109506.7 1991-05-02

Publications (1)

Publication Number Publication Date
CA2102120A1 true CA2102120A1 (fr) 1992-11-03

Family

ID=10694346

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002102120A Abandoned CA2102120A1 (fr) 1991-05-02 1992-05-01 Utilisation d'un derive 1,3-oxathlolane pour le traitement de l'hepatite b

Country Status (14)

Country Link
EP (1) EP0583274A1 (fr)
JP (1) JPH06506929A (fr)
AU (1) AU1662092A (fr)
CA (1) CA2102120A1 (fr)
GB (1) GB9109506D0 (fr)
IE (1) IE921363A1 (fr)
IL (1) IL101757A0 (fr)
MX (1) MX9203214A (fr)
MY (1) MY137298A (fr)
PT (1) PT100435B (fr)
RU (1) RU2104700C1 (fr)
UA (1) UA37251C2 (fr)
WO (1) WO1992019246A1 (fr)
ZA (1) ZA923185B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5684164A (en) 1988-04-11 1997-11-04 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
OA11741A (en) 1998-12-23 2005-05-13 Iaf Biochem Int Antiviral nucleoside analogues.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5159067A (en) * 1987-01-28 1992-10-27 University Of Georgia Research Foundation Inc. 5'-Diphosphohexose nucleoside pharmaceutical compositions
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
CA2055433A1 (fr) * 1989-05-15 1990-11-16 Jay H. Hoofnagle Methode de traitement de l'hepatite
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds

Also Published As

Publication number Publication date
RU2104700C1 (ru) 1998-02-20
AU1662092A (en) 1992-12-21
EP0583274A1 (fr) 1994-02-23
PT100435B (pt) 1999-08-31
IL101757A0 (en) 1992-12-30
MX9203214A (es) 1992-07-01
UA37251C2 (uk) 2001-05-15
JPH06506929A (ja) 1994-08-04
IE921363A1 (en) 1992-11-04
PT100435A (pt) 1993-09-30
WO1992019246A1 (fr) 1992-11-12
GB9109506D0 (en) 1991-06-26
ZA923185B (en) 1993-11-01
MY137298A (en) 2009-01-30

Similar Documents

Publication Publication Date Title
EP0574487B1 (fr) Utilisation de 5-fluoro-2'-desoxy-3'-thiacytidine pour le traitement de l'hepatite b
IE84129B1 (en) Therapeutic nucleosides
CA2102120A1 (fr) Utilisation d'un derive 1,3-oxathlolane pour le traitement de l'hepatite b
US20060229327A1 (en) Therapeutic nucleosides
CA2044125A1 (fr) Nucleoside de pyrimidine antivhb
EP0620734A1 (fr) Nucleosides a usage therapeutique
NZ264990A (en) Use of 1-(2-(hydroxymethyl))-1,3-oxathiolan-5-yl)cytosine derivatives to prepare medicaments and methods of treatment of hepatitas b virus infections
CA2439322A1 (fr) Nucleosides therapeutiques
IE85820B1 (en) Use of 5 - fluoro -2'deoxy-3' thiacytidine for the treatment of hepatitis B

Legal Events

Date Code Title Description
FZDE Discontinued